UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2020-10, Vol.396 (10257), p.1090-1100

2020

Volltextzugriff (PDF)

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Clinical cancer research, 2016-08, Vol.22 (15), p.3764-3773

2016

Volltextzugriff (PDF)

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2018-08, Vol.36 (23), p.2433-2443

2018

Volltextzugriff (PDF)

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2017-12, Vol.114 (52), p.13792-13797

2017

Volltextzugriff (PDF)

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

PloS one, 2012-05, Vol.7 (5), p.e33788-e33788

2012

Volltextzugriff (PDF)

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Journal of clinical oncology, 2016-07, Vol.34 (20), p.2416-2427

2016

Volltextzugriff (PDF)

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Journal of clinical oncology, 2007-08, Vol.25 (23), p.3525-3533

2007

Volltextzugriff (PDF)

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2851-2858

2018

Volltextzugriff (PDF)

Induced Pluripotent Stem Cell-Based Cancer Vaccines

Frontiers in immunology, 2019-07, Vol.10, p.1510-1510

2019

Volltextzugriff (PDF)

Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

Nature communications, 2023-04, Vol.14 (1), p.2053-2053, Article 2053

2023

Volltextzugriff (PDF)

Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations

Stem cell research, 2023-12, Vol.73, p.103246-103246, Article 103246

2023

Volltextzugriff (PDF)

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry

Breast cancer research and treatment, 2011-06, Vol.127 (2), p.471-478

2011

Volltextzugriff (PDF)

Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants

Stem cell research, 2023-10, Vol.72, p.103219-103219, Article 103219

2023

Volltextzugriff (PDF)

BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

The lancet oncology, 2020-10, Vol.21 (10), p.1254-1255

Telli, Melinda L

2020

Volltextzugriff (PDF)

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study

NPJ breast cancer, 2021-05, Vol.7 (1), p.57-57, Article 57

2021

Volltextzugriff (PDF)

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

NPJ breast cancer, 2022-04, Vol.8 (1), p.45-9, Article 45

2022

Volltextzugriff (PDF)

Genetics of triple-negative breast cancer: Implications for patient care

Current problems in cancer, 2016-03, Vol.40 (2-4), p.130-140

2016

Volltextzugriff (PDF)

Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2451-2465

2019

Volltextzugriff (PDF)

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

NPJ breast cancer, 2023-10, Vol.9 (1), p.81-81, Article 81

2023

Volltextzugriff (PDF)

Phyllodes tumors of the breast: natural history, diagnosis, and treatment

Journal of the National Comprehensive Cancer Network, 2007-03, Vol.5 (3), p.324

2007

Volltextzugriff (PDF)

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Clinical cancer research, 2019-05, Vol.25 (9), p.2717-2724

2019

Volltextzugriff (PDF)

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-02, Vol.39 (6), p.685-693

2021

Volltextzugriff (PDF)

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Clinical cancer research, 2017-10, Vol.23 (19), p.5687-5695

2017

Volltextzugriff (PDF)

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Journal of clinical oncology, 2015-06, Vol.33 (17), p.1895-1901

2015

Volltextzugriff (PDF)

Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer

Annals of surgical oncology, 2016-10, Vol.23 (10), p.3310-3316

2016

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(113)

Publikationsform

Artikel
(128)
Buchkapitel
(1)

Sprache

Englisch
(129)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(66)
Life Sciences & Biomedicine
(63)
Humans
(56)
Oncology
(54)
Female
(50)
Breast Cancer
(24)
Middle Aged
(17)
Tumors
(17)
Breast Neoplasms - Drug Therapy
(16)
Mutation
(15)
Adult
(14)
Chemotherapy
(13)
Breast Neoplasms - Genetics
(11)
Breast Neoplasms - Pathology
(11)
Cancer
(10)
Cancer Therapies
(10)
Triple Negative Breast Neoplasms - Drug Therapy
(10)
Aged
(9)
Antineoplastic Agents - Therapeutic Use
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Induced Pluripotent Stem Cell-Based Cancer Vaccines

Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry

Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants

BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Genetics of triple-negative breast cancer: Implications for patient care

Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

Phyllodes tumors of the breast: natural history, diagnosis, and treatment

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer

Suchergebnisse filtern